Fahr's Disease

Fahr's Disease

Fahr's Disease, also known as Fahr's syndrome or Familial Cerebrovascular Ferrocalcinosis, is a rare hereditary neurodegenerative disorder characterized by bilateral calcification of the basal ganglia and other brain regions. First described by Karl Theodor Fahr in 1930, this condition is classified among the Neurodegeneration with Brain Iron Accumulation (NBIA) disorders.

Overview

• Full Name: Fahr's Disease / Idiopathic Familial Cerebral Ferrocalcinosis
• Synonyms: Fahr's syndrome, Striopallidodentate calcinosis, Cerebrotendinous calcification
• Classification: Neurodegeneration with Brain Iron Accumulation (NBIA) / Movement Disorder / Neurogenetic Disorder
• ICD-10 Code: G23.8 (Other degenerative diseases of basal ganglia)

Epidemiology

• Prevalence: Approximately 1 in 1,000,000 individuals
• Inheritance: Autosomal dominant (most cases); sporadic cases also reported
• Age of Onset: Highly variable (2nd to 7th decade), typically in middle age
• Gender Distribution: Slight male predominance reported in some studies

Genetics

Inheritance Pattern

Fahr's disease follows an autosomal dominant inheritance pattern with high penetrance. Multiple family generations may be affected[@roubergue2013].

Gene Mutations

Mutations in the following genes are associated with Fahr's disease[@roubergue2013][@baker2014]:

SLC20A2 (Phosphate transporter 2)

• Most common causative gene
• Encodes PiT2, a phosphate transporter
• Accounts for approximately 40% of familial cases

...

Fahr's Disease

Fahr's Disease, also known as Fahr's syndrome or Familial Cerebrovascular Ferrocalcinosis, is a rare hereditary neurodegenerative disorder characterized by bilateral calcification of the basal ganglia and other brain regions. First described by Karl Theodor Fahr in 1930, this condition is classified among the Neurodegeneration with Brain Iron Accumulation (NBIA) disorders.

Overview

• Full Name: Fahr's Disease / Idiopathic Familial Cerebral Ferrocalcinosis
• Synonyms: Fahr's syndrome, Striopallidodentate calcinosis, Cerebrotendinous calcification
• Classification: Neurodegeneration with Brain Iron Accumulation (NBIA) / Movement Disorder / Neurogenetic Disorder
• ICD-10 Code: G23.8 (Other degenerative diseases of basal ganglia)

Epidemiology

• Prevalence: Approximately 1 in 1,000,000 individuals
• Inheritance: Autosomal dominant (most cases); sporadic cases also reported
• Age of Onset: Highly variable (2nd to 7th decade), typically in middle age
• Gender Distribution: Slight male predominance reported in some studies

Genetics

Inheritance Pattern

Fahr's disease follows an autosomal dominant inheritance pattern with high penetrance. Multiple family generations may be affected[@roubergue2013].

Gene Mutations

Mutations in the following genes are associated with Fahr's disease[@roubergue2013][@baker2014]:

SLC20A2 (Phosphate transporter 2)

• Most common causative gene
• Encodes PiT2, a phosphate transporter
• Accounts for approximately 40% of familial cases

PDGFRB (Platelet-Derived Growth Factor Receptor Beta)

• Second most common gene
• Encodes a receptor tyrosine kinase

PLCB4 (Phospholipase C Beta 4)

• Rare causative mutation

JAM2 (Junctional Adhesion Molecule 2)

• Very rare cause

Pathophysiology of Gene Mutations

• SLC20A2 mutations: Impair phosphate transport, leading to abnormal calcium/iron deposition[@roubergue2013]
• PDGFRB mutations: Affect vascular integrity and mineral metabolism[@baker2014]
• PLCB4 mutations: Disrupt cellular signaling pathways

Clinical Features

Neurological Symptoms

Movement Disorders

• Parkinsonism: Bradykinesia, rigidity, tremor
• Dystonia: Involuntary muscle contractions
• Chorea: Involuntary jerky movements
• Ataxia: Coordination difficulties

Cognitive Impairment

• Progressive dementia
• Executive function deficits
• Memory impairment
• Behavioral changes

Psychiatric Manifestations

• Depression
• Anxiety
• Personality changes
• Psychosis (rare)

Other Symptoms

• Seizures: May occur in some patients
• Headache: Chronic or recurrent
• Speech difficulties: Dysarthria
• Swallowing difficulties: Dysphagia

Neuroimaging

CT Scan Findings

The hallmark finding is bilateral, symmetric calcifications:

• Basal ganglia (globus pallidus, putamen, caudate)
• Dentate nucleus of cerebellum
• Thalamus
• Subcortical white matter

MRI Findings

• T2 hyperintensities in affected regions
• May show iron deposition on susceptibility-weighted imaging
• Progressive brain atrophy in advanced cases

Diagnosis

Diagnostic Criteria

Neuroimaging: Bilateral calcification of basal ganglia on CT

Clinical presentation: Movement disorder + cognitive decline

Exclusion: Exclusion of other causes (infectious, metabolic, toxic)

Differential Diagnosis

• [Parkinson's disease](/diseases/parkinsons-disease)
• [Huntington's disease](/diseases/huntington-disease)
• [Wilson's disease](/diseases/wilson-disease)
• [Hypoparathyroidism](/diseases/hypoparathyroidism)
• [Cockayne syndrome](/diseases/cockayne-syndrome)

Genetic Testing

• SLC20A2 sequencing
• PDGFRB sequencing
• PLCB4 sequencing
• JAM2 sequencing

Pathophysiology

Mechanism of Mineral Deposition

The primary abnormality involves disrupted phosphate and mineral homeostasis[@zhang2019]:

Impaired phosphate transport (SLC20A2 mutations)

Abnormal cellular mineral metabolism

Progressive calcium and iron deposition

Neurotoxicity from mineral accumulation

Neurodegeneration

• Iron deposition leads to oxidative stress[@zhang2019]
• Mitochondrial dysfunction
• Neuronal loss in affected regions
• Progressive cerebral atrophy

Management

Symptomatic Treatment

Movement Disorders

• Levodopa: May provide benefit for parkinsonism
• Anticholinergics: For dystonia
• Botulinum toxin: For focal dystonia
• Benzodiazepines: For chorea

Cognitive/Psychiatric Symptoms

• [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors): For dementia
• Antidepressants: For depression
• Antipsychotics: For psychosis (use cautiously)

Experimental Approaches

• Iron chelation therapy: Deferoxamine trials
• Phosphate binders: Sevelamer
• Gene therapy: Under investigation

Prognosis

• Course: Progressive, but variable rate
• Life expectancy: Often normal with appropriate management
• Disability: Variable, from mild to severe impairment
• Treatment response: Often partial and temporary

Related Conditions

• [Neurodegeneration with brain iron accumulation (NBIA)](/diseases/neurodegeneration-with-brain-iron-accumulation)))))))))))
• [Parkinsonism](/mechanisms/parkinsonism)
• [Basal ganglia disorders](/mechanisms/basal-ganglia)
• [Movement disorders](/mechanisms/movement-disorders)

See Also

• [Parkinson's disease](/diseases/parkinsons-disease)
• [Huntington's disease](/diseases/huntington-disease)
• [Wilson's disease](/diseases/wilson-disease)
• [Hypoparathyroidism](/diseases/hypoparathyroidism)
• [Cockayne syndrome](/diseases/cockayne-syndrome)
• [Neurodegeneration with brain iron accumulation (NBIA)](/diseases/neurodegeneration-with-brain-iron-accumulation)))))))))))
• [Parkinsonism](/mechanisms/parkinsonism)
• [Basal ganglia disorders](/mechanisms/basal-ganglia)
• [Movement disorders](/mechanisms/movement-disorders)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Fahr, idiopatische familiäre Cerebralkalkose (1930) (1930)](https://doi.org/10.1007/BF01647313)

[Roubergue et al., SLC20A2 mutations in Fahr disease (2013) (2013)](https://doi.org/10.1093/brain/awt052)

[Baker et al., PDGFRB mutations and Fahr disease (2014) (2014)](https://doi.org/10.1093/jmedgenet/jkv037)

[Ward et al., NBIA: Classification and clinical features (2020) (2020)](https://doi.org/10.1002/mdc3.12999)

[Zhang et al., Iron deposition in neurodegenerative diseases (2019) (2019)](https://doi.org/10.1007/s12035-019-1563-9)